Comparison of octreotide and proton pump inhibitor in the prevention of acute pancreatitis after endoscopic retrograde cholangiopancreatography for different diseases

This study compared the role of octreotide and proton pump inhibitor (PPI) in preventing acute pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). The 320 patients who received ERCP from January 2019 to June 2022 were randomly and evenly divided into octreotide, PPI, combined treatment and control groups. The incidence of post-ERCP acute pancreatitis (PEP) and hyperamylasemia was counted. The incidence of PEP and hyperamylasemia after surgery differed significantly among all groups. For incidence of PEP, it was similar in the control, octreotide and PPI groups (12.50%, 8.75% and 10.00%), all of which were higher than that of the combined treatment group (1.25%). The incidence of hyperamylasemia was similar between the octreotide and PPI groups (12.50% and 13.75%), both decreased compared with the control group (32.50%), and further lowered in the combined treatment group (8.75%), and all differences were statistically significant (p < 0.05). For patients with choledocholithiasis, the incidence of hyperamylasemia in the combined treatment group was lower than that in the other three groups (8.33%, 31.25%, 21.43% and 16.67%) after intervention, while there were no significant differences in the incidence of PEP and hyperamylasemia in patients with cholangiocarcinoma, pancreatic head carcinoma and other lesions. In conclusion, preoperative application of octreotide or PPI alone has a slight effect on preventing PEP and hyperamylasemia after ERCP, and their combination is dramatically effective in preventing PEP.

ERCP; Acute pancreatitis; Hyperamylasemia; Octreotide; PPI

[1] Itoi T. Pancreatobiliary endoscopy: diagnostic endoscopic retrograde cholangiopancreatography. Digestive Endoscopy. 2022; 34: 99–101.

[2] Park CH. The latest knowledge on endoscopic retrograde cholangiopancreatography-related pancreatitis. The Korean Journal of Gastroenterology. 2022; 79: 195–198. (In Korean)

[3] Johnson KD, Perisetti A, Tharian B, Thandassery R, Jamidar P, Goyal H, et al. Endoscopic retrograde cholangiopancreatography-related complications and their management strategies: a “scoping” literature review. Digestive Diseases and Sciences. 2020; 65: 361–375.

[4] Asenov Y, Akın M, Cantez S, Soysal FG, Tekant Y. Endoscopic retrograde cholangiopancreatography in children: retrospective series with a long-term follow-up and literature review. The Turkish Journal of Gastroenterology. 2019; 30: 192–197.

[5] Weiland CJS, Smeets XJNM, Umans DS, Drenth JPH, van Geenen EJM. Aggressive hydration and post-ERCP pancreatitis—authors’ reply. The Lancet Gastroenterology and Hepatology. 2021; 6: 686–687.

[6] Aljohani S, Mirghani H. Aggressive hydration with ringer’s lactate in the prevention of post-ERCP pancreatitis: a meta-analysis. Cureus. 2021; 13: e14897.

[7] Ru N, Qian YY, Zhu JH, Chen H, Zou WB, Hu LH, et al. Post‐ESWL and post‐ERCP pancreatitis in patients with chronic pancreatitis: do they share the same risks? Journal of Hepato-Biliary-Pancreatic Sciences. 2021; 28: 778–787.

[8] García-Cano J, de la Santa Belda E, Domper F. Use a biodegradable stent in ERCP and it will never be forgotten. Revista Espanola De Enfermedades Digestivas. 2022; 114: 513–515.

[9] Sperna Weiland CJ, Smeets XJNM, Kievit W, Verdonk RC, Poen AC, Bhalla AC, et al. Aggressive fluid hydration plus non-steroidal anti-inflammatory drugs versus non-steroidal anti-inflammatory drugs alone for post-endoscopic retrograde cholangiopancreatography pancreatitis (FLUYT): a multicentre, open-label, randomised, controlled trial. The Lancet Gastroenterology and Hepatology. 2021; 6: 350–358.

[10] Kim JS, Lee SH, Park N, Huh G, Chun JW, Choi JH, et al. The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis. BMC Gastroenterology. 2022; 22: 271.

[11] Chen Z, Fu H, Fang J, Yang J, Zhu X, Cheng B, et al. Preventive and therapeutic significance of octreotide combined with lansoprazole on post-ERCP pancreatitis and its effect on serum amylase, inflammatory factors and immune function. Experimental and Therapeutic Medicine. 2021; 21: 251.

[12] Wang J, Shen Y, Zhong Z, Wu S, Zheng L. Risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and the effect of octreotide combined with nonsteroidal anti-inflammatory drugs on preventing its occurrence. Medical Science Monitor. 2018; 24: 8964–8969.

[13] Cahyadi O, Tehami N, de-Madaria E, Siau K. Post-ERCP pancreatitis: prevention, diagnosis and management. Medicina. 2022; 58: 1261.

[14] Hakuta R, Nakai Y, Hamada T, Nomura Y, Saito T, Takahara N, et al. Use of proton pump inhibitors and cholangitis complicated with multi-drug resistant bacteria. Journal of Hepato-Biliary-Pancreatic Sciences. 2022; 29: 230–238.

[15] Hakuta R, Nakai Y, Oyama H, Noguchi K, Kanai S, Nomura Y, et al. Increased risk of biliary infection after biliary stent placement in users of proton pump inhibitors. DEN Open. 2023; 3: e129.

[16] Smeets X, Bouhouch N, Buxbaum J, Zhang H, Cho J, Verdonk RC, et al. The revised Atlanta criteria more accurately reflect severity of post-ERCP pancreatitis compared to the consensus criteria. United European Gastroenterology Journal. 2019; 7: 557–564.

[17] Lyu Y, Cheng Y, Li T, Cheng B, Jin X. Laparoscopic common bile duct exploration plus cholecystectomy versus endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy for chole-cystocholedocholithiasis: a meta-analysis. Surgical Endoscopy. 2019; 33: 3275–3286.

[18] Jang DK, Kim J, Paik CN, Kim JW, Lee TH, Jang JY, et al. Endoscopic retrograde cholangiopancreatography‐related adverse events in Korea: a nationwide assessment. United European Gastroenterology Journal. 2022; 10: 73–79.

[19] Naitoh I, Nakazawa T. Endoscopic retrograde cholangiopancreatography and intraductal ultrasonography in the diagnosis of autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Journal of Medical Ultrasonics. 2021; 48: 573–580.

[20] Akshintala VS, Sperna Weiland CJ, Bhullar FA, Kamal A, Kanthasamy K, Kuo A, et al. Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis. The Lancet Gastroenterology and Hepatology. 2021; 6: 733–742.

[21] Chiba M, Kato M, Kinoshita Y, Shimamoto N, Tomita Y, Abe T, et al. The milestone for preventing post-ERCP pancreatitis using novel simplified predictive scoring system: a propensity score analysis. Surgical Endoscopy. 2021; 35: 6696–6707.

[22] Park CH, Park SW, Yang MJ, Moon SH, Park DH. Pre- and post-procedure risk prediction models for post-endoscopic retrograde cholan-giopancreatography pancreatitis. Surgical Endoscopy. 2022; 36: 2052–2061.

[23] Köseoğlu H, Solakoğlu T, Başaran M, Özer Sarı S, Tahtacı M, Yaman S, et al. Risk factors for post-ERCP pancreatitis: it depends on the ERCP indication. Acta Gastro-Enterologica Belgica. 2020; 83: 598–602.

[24] Chen MJ, Zheng RH, Cao J, Yao YL, Wang L, Zou XP. Risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) abdom-inal pain in patients without post-ERCP pancreatitis. Hepatobiliary & Pancreatic Diseases International. 2022; 21: 285–292.

[25] Issak A, Elangovan A, Ferguson RD, Waghray N, Sandhu DS. Underutilization of prophylactic rectal indomethacin and pancreatic duct stent for prevention of post-ERCP Pancreatitis. Endoscopy International Open. 2021; 9: E979–E985.

[26] Zhou X, Long J, Wang H, Yi S, Zhao J. Clinical observation of octreotide combined with diclofenac sodium in preventing ERCP-related pancreatitis. American Journal of Translational Research. 2021; 13: 7179–7185.

[27] Mitra S, Hussain MS, Rahman R, Salam MA, Mazumder T, Farzana S. A survey on the incidence of common musculoskeletal side effects among the patients taking long-term anti-ulcerant therapies in Bangladesh. Toxicology Reports. 2022; 9: 1796–1805.

[28] van der Merwe SW, van Wanrooij RLJ, Bronswijk M, Everett S, Lakhtakia S, Rimbas M, et al. Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2022; 54: 185–205.

[29] Zhang Y, Chen QB, Gao ZY, Xie WF. Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses. Alimentary Pharmacology & Therapeutics. 2009; 29: 1155–1164.

[30] Li ZS, Pan X, Zhang WJ, Gong B, Zhi FC, Guo XG, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: a multicenter, placebo-controlled, randomized clinical trial. The American Journal of Gastroenterology. 2007; 102: 46–51.

[31] Shi QQ, Huang GX, Li W, Yang JR, Ning XY. Rectal nonsteroidal anti-inflammatory drugs, glyceryl trinitrate, or combinations for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: a network meta-analysis. World Journal of Clinical Cases. 2022; 10: 7859–7871.

[32] Akshintala VS, Husain SZ, Brenner TA, Singh A, Singh VK, Khashab MA, et al. Rectal indomethacin, oral tacrolimus, or their combination for the prevention of post-ERCP pancreatitis (INTRO Trial): protocol for a randomized, controlled, double-blinded trial. Pancreatology. 2022; 22: 887–893.